Blood:CDC42调控白血病细胞对称性分裂、抑制其分化。

2017-08-07 qinqiyun MedSci原创

作为细胞极性的中心调控,CDC42 GTPase的活性在维持正常的造血干细胞和祖细胞(HSC / P)功能上受到精密调控。研究发现,HSC/P转化成急性髓性白血病(AML)与CDC42在白血病细胞中的表达上调和活性增强相关。

中心点:

CDC42调控AML细胞极性及其对称性分裂。

抑制AML细胞表达CDC42,可促进白血病细胞分化,抑制其继续进展。

摘要:

作为细胞极性的中心调控,CDC42 GTPase的活性在维持正常的造血干细胞和祖细胞(HSC / P)功能上受到精密调控。研究发现,HSC/P转化成急性髓性白血病(AML)与CDC42在白血病细胞中的表达上调和活性增强相关。
在AML的小鼠模型中,Cdc42丢失可抑制MLL-AF9诱导的AML进展。而且,在小鼠和人MLL-AF9(MA9)细胞中CDC42的遗传消融可减少无性克隆白血病原始细胞的存活和诱导分化。

Benjamin Mizukawa等人还发现提高Cdc42-GTP的活性,类似于幼稚HSC/P环境,MLL-AF9白血病细胞可维持细胞极性。Cdc42丢失会促进转变成去极化化的AML细胞,这与生成可自我更新的子细胞的对称和非对称性细胞分裂频率降低有关。重要的是,研究人员证明在人类患者的原代AML细胞中诱导CDC42表达可抑制移植瘤模型的白血病进展。

因此,CDC42丢失可抑制AML细胞极性,并抑制其不对称性分裂,CDC42为分化疗法提供一有效靶点,改变白血病原始细胞的结局。

原始出处:

Benjamin Mizukawa,Eric O'Brien,et al.Cell polarity determinant CDC42 controls division symmetry to block leukemia cell differentiation.Blood.August o4,2017. https://doi.org/10.1182/blood-2016-12-758458

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

评论区 (2)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1558452, encodeId=a788155845208, content=<a href='/topic/show?id=1c59438679' target=_blank style='color:#2F92EE;'>#CDC42#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4386, encryptionId=1c59438679, topicName=CDC42)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23db14986201, createdName=hongbochen, createdTime=Wed Aug 09 05:54:00 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564461, encodeId=1b5615644615e, content=<a href='/topic/show?id=1c59438679' target=_blank style='color:#2F92EE;'>#CDC42#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4386, encryptionId=1c59438679, topicName=CDC42)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23db14986201, createdName=hongbochen, createdTime=Wed Aug 09 05:54:00 CST 2017, time=2017-08-09, status=1, ipAttribution=)]
    2017-08-09 hongbochen

    #CDC42#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1558452, encodeId=a788155845208, content=<a href='/topic/show?id=1c59438679' target=_blank style='color:#2F92EE;'>#CDC42#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4386, encryptionId=1c59438679, topicName=CDC42)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23db14986201, createdName=hongbochen, createdTime=Wed Aug 09 05:54:00 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564461, encodeId=1b5615644615e, content=<a href='/topic/show?id=1c59438679' target=_blank style='color:#2F92EE;'>#CDC42#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4386, encryptionId=1c59438679, topicName=CDC42)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23db14986201, createdName=hongbochen, createdTime=Wed Aug 09 05:54:00 CST 2017, time=2017-08-09, status=1, ipAttribution=)]
    2017-08-09 hongbochen

    #CDC42#

    0